机构：[1]Center for Translational Medicine, The Third People's Hospital of Longgang District, Shenzhen 518112, China.[2]Inner Mongolia Key Laboratory of Hypoxic Translational Medicine, Baotou Medical College, Baotou 014060, China.内蒙古科技大学包头医学院[3]Institute for Neuroscience, Baotou Medical College, Baotou 014060, China.内蒙古科技大学包头医学院[4]Department of Emergency, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.内科系统急诊科首都医科大学宣武医院[5]Beijing Institute of Brain Disorders, Capital Medical University, Beijing 100069, China.[6]Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI 48021, USA.[7]Department of Oral and Maxillofacial Surgery, University of California San Francisco, San Francisco, CA 94143, USA.[8]Beijing Key Laboratory of Hypoxic Conditioning Translational Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.科技平台低氧适应转化医学北京市重点实验室首都医科大学宣武医院[9]Department of Neurosurgery, The First Affiliated Hospital of Baotou Medical College, Baotou 014010, China.内蒙古科技大学包头医学院
Hypoxic and ischemic brain injury can cause neurological disability and mortality, and has become a serious public health problem worldwide. Long-chain non-coding RNAs are involved in the regulation of many diseases. Metastasis-related lung adenocarcinoma transcript 1 (MALAT1) is a type of long non-coding RNA (lncRNA), known as long intergenic non-coding RNA (lincRNA), and is highly abundant in the nervous system. The enrichment of MALAT1 in the brain indicates that it may be associated with important functions in pathophysiological processes. Accordingly, the role of MALAT1 in neuronal cell hypoxic/ischemic injury has been gradually discovered over recent years. In this article, we summarize recent research regarding the neuroprotective molecular mechanism of MALAT1 and its regulation of pathophysiological processes of brain hypoxic/ischemic injury. MALAT1 may function as a regulator through interaction with proteins or RNAs to perform its role, and may therefore serve as a therapeutic target in cerebral hypoxia/ischemia.
基金：
This research was funded by National Natural Science Foundation (82160250, 82060337,
81801313), Beijing Municipal Administration of Hospitals Incubating Program (PX2019028) and
Shenzhen Longgang District Economic and Technological Development Special Fund Medical and
Health Technology Plan Project (LGKCYLWS2021000033).
第一作者机构：[1]Center for Translational Medicine, The Third People's Hospital of Longgang District, Shenzhen 518112, China.[2]Inner Mongolia Key Laboratory of Hypoxic Translational Medicine, Baotou Medical College, Baotou 014060, China.[3]Institute for Neuroscience, Baotou Medical College, Baotou 014060, China.
共同第一作者：
通讯作者：
通讯机构：[1]Center for Translational Medicine, The Third People's Hospital of Longgang District, Shenzhen 518112, China.[2]Inner Mongolia Key Laboratory of Hypoxic Translational Medicine, Baotou Medical College, Baotou 014060, China.[3]Institute for Neuroscience, Baotou Medical College, Baotou 014060, China.[8]Beijing Key Laboratory of Hypoxic Conditioning Translational Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.[9]Department of Neurosurgery, The First Affiliated Hospital of Baotou Medical College, Baotou 014010, China.
推荐引用方式(GB/T 7714)：
Wang Liping,Li Sijie,Stone Sara Saymuah,et al.The Role of the lncRNA MALAT1 in Neuroprotection against Hypoxic/Ischemic Injury.[J].BIOMOLECULES.2022,12(1):doi:10.3390/biom12010146.
APA：
Wang Liping,Li Sijie,Stone Sara Saymuah,Liu Na,Gong Kerui...&Shao Guo.(2022).The Role of the lncRNA MALAT1 in Neuroprotection against Hypoxic/Ischemic Injury..BIOMOLECULES,12,(1)
MLA：
Wang Liping,et al."The Role of the lncRNA MALAT1 in Neuroprotection against Hypoxic/Ischemic Injury.".BIOMOLECULES 12..1(2022)
